Over the 90-day window ending January 10, 2026, Keros Therapeutics's three dominant insider ownership positions are held by Director Tomer Kariv (1.23Mn shares), Director Ran Nussbaum (1.23Mn shares), Chief Executive Officer Jasbir Seehra (392.72K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Ran Nussbaum | 1,231,662 | 06 Jun, 2025 | |
| Tomer Kariv | 1,231,662 | 06 Jun, 2025 | |
| Jasbir Seehra | Chief Executive Officer | 392,723 | 05 Sep, 2025 |
| Julius Knowles | 108,674 | 06 Jun, 2025 | |
| Jennifer Lachey | Chief Scientific Officer | 95,100 | 19 Jul, 2022 |
| Christopher Rovaldi | Chief Operating Officer | 60,000 | 19 Feb, 2025 |
| Carl L Gordon | 50,307 | 06 Jun, 2025 | |
| Advisors Llc Orbimed | 45,057 | 18 Dec, 2025 | |
| Keith Regnante | Chief Financial Officer | 44,000 | 19 Feb, 2025 |
| Yung H. Chyung | Chief Medical Officer | 44,000 | 19 Feb, 2025 |
| Jean Jacques Bienaime | 5,450 | 06 Jun, 2025 | |
| Nima Farzan | 5,250 | 06 Jun, 2025 | |
| Mary Ann Gray | 5,250 | 06 Jun, 2025 | |
| Alpna Seth | 5,250 | 06 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 21 Nov, 2025 | Advisors Llc Orbimed | Common Stock | D | 140,057 | $17.75 | 759,155 | I | D |
| 21 Nov, 2025 | Advisors Llc Orbimed | Common Stock | D | 74,465 | $17.75 | 45,057 | I | D |
| 21 Nov, 2025 | Carl L Gordon | Common Stock | D | 140,057 | $17.75 | 759,155 | I | D |
| 21 Nov, 2025 | Carl L Gordon | Common Stock | D | 74,465 | $17.75 | 45,057 | I | D |
| 21 Nov, 2025 | Julius Knowles | Common Stock | D | 191,527 | $17.75 | 150,047 | I | D |
| 21 Nov, 2025 | Julius Knowles | Common Stock | D | 130,494 | $17.75 | 102,233 | I | D |
| 15 Oct, 2025 | Management 4 G.P. (2015) Ltd. Pontifax | Common Stock, $0.0001 par value per share | D | 1,226,412 | $17.75 | 0 | I | S |
| 15 Oct, 2025 | Management 4 G.P. (2015) Ltd. Pontifax | Common Stock, $0.0001 par value per share | D | 155,262 | $17.75 | 0 | I | S |
| 15 Oct, 2025 | Management 4 G.P. (2015) Ltd. Pontifax | Common Stock, $0.0001 par value per share | D | 1,121,045 | $17.75 | 0 | I | S |
| 15 Oct, 2025 | Management 4 G.P. (2015) Ltd. Pontifax | Common Stock, $0.0001 par value per share | D | 2,284,612 | $17.75 | 0 | I | S |
| 15 Oct, 2025 | Capital Management, Llc Adar1 | Common Stock | D | 4,391,237 | $17.75 | 0 | I | S |
| 15 Oct, 2025 | Capital Management, Llc Adar1 | Common Stock | D | 743,358 | $17.75 | 0 | I | S |
| 15 Oct, 2025 | Capital Management, Llc Adar1 | Common Stock | D | 254,669 | $17.75 | 0 | I | S |
| 03 Sep, 2025 | Jasbir Seehra | Common Stock | A | 90,500 | $0.00 | 392,723 | D | A |
| 03 Sep, 2025 | Jasbir Seehra | - | - | 392,723 | D | |||
| 20 Jun, 2025 | Capital Management, Llc Adar1 | Common Stock | D | 100 | $60.00 | 4,392,637 | I | X |
| 20 Jun, 2025 | Capital Management, Llc Adar1 | Common Stock | D | 1,400 | $70.00 | 4,391,237 | I | X |
| 20 Jun, 2025 | Capital Management, Llc Adar1 | Common Stock | D | 200 | $70.00 | 743,358 | I | X |
| 04 Jun, 2025 | Jean Jacques Bienaime | Common Stock | A | 5,250 | $0.00 | 5,450 | D | A |
| 04 Jun, 2025 | Mary Ann Gray | Common Stock | A | 5,250 | $0.00 | 5,250 | D | A |